home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2842.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
35 lines
Document 2842
DOCN M94A2842
TI Phase II study of combination of lentinan with ddI in HIV-positive
patients.
DT 9412
AU Kaneko Y; Mimura T; Guralnik M; Baker M; Goodgame J; DeMarzo C; Pierce
D; Lang W; Gordon M; Ajinomoto Co., Inc., Tokyo, Japan.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):212 (abstract no. PB0276). Unique
Identifier : AIDSLINE ICA10/94369733
AB OBJECTIVE: To assess the safety and efficacy of a combination of ddI
(didanosine) and lentinan (an immune modulator) in HIV-positive cases.
METHODS: Didanosine was administered to HIV-positive individuals with
CD4 levels of 200-500 cells/cmm at a dose of 400 mg/day (po) for six
weeks (bid), then 2 mg of lentinan iv was added per week for 24-80
weeks. A control group (20%) received ddI only. About 70 patients have
been enrolled to date out of a target of 100 patients. Laboratory
parameters measured were CD4, p24 antigen, chemistry, hematology and
T-cell panels. RESULTS: The combination was well tolerated and no
unexpected side effects were observed. Patients generally had improved
CD4 levels and a reduction in p24 antigen, although the study is still
blinded. CONCLUSION: Because of the refractory nature of HIV disease it
is recommended that the above combination of ddI and lentinan be
supplemented with interleukin-2 and/or curdlan sulfate.
DE Adjuvants, Immunologic/*THERAPEUTIC USE Combined Modality Therapy
Comparative Study Didanosine/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE
Glucans/ADMINISTRATION & DOSAGE/THERAPEUTIC USE Human HIV
Infections/DRUG THERAPY/*THERAPY Interleukin-2/ADMINISTRATION &
DOSAGE/THERAPEUTIC USE Lentinan/ADMINISTRATION & DOSAGE/*THERAPEUTIC
USE Safety Treatment Outcome CLINICAL TRIAL CLINICAL TRIAL, PHASE II
MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).